New Stroke Drug Saves Money While Reducing Disability
American Academy of Neurology (AAN)Stroke patients treated with the new stroke drug tissue plasminogen activator (t-PA) generally have better outcomes and therefore are less costly to the health care system than those not treated, according to an article published in the April issue of Neurology, the scientific journal of the American Academy of Neurology.